Abstract
AEROSOL DELIVERY of pentamidine may be the key to effective prophylaxis and therapy for<i>Pneumocystis carinii</i>pneumonia (PCP) in patients with acquired immunodeficiency syndrome (AIDS). According to early studies, not only does the aerosolized form of the drug appear to eradicate and prevent PCP, it does so without many of the serious side effects associated with parenterally administered pentamidine. The results have prompted two companies, LyphoMed, Inc, Melrose Park, Ill, and Fisons Corporation, Bedford, Mass, to compete for the exclusive rights to market it under the Food and Drug Administration's (FDA) Orphan Drug Act. Both companies are sponsoring extensive clinical trials. LyphoMed, which is backing trials at San Francisco General Hospital, already has exclusive US marketing rights for intravenous and intramuscular pentamidine for the treatment of PCP until 1991. However, that exclusivity applies only to parenteral delivery and an indication for treatment. LyphoMed would also like to have a monopoly
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call